Q32 Bio Initiates First-in-Human Phase 1 Clinical Study of ADX-097 for the Treatment of Complement Disorders
First clinical-stage program from Q32 Bio’s tissue targeted complement inhibitor platform Clinical-stage pipeline now consists of two programs in development to restore immune homeostasis Waltham, Mass. – May 26, 2022 — Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been initiated in the healthy volunteer portion […] Read More >